Clinical trials: Botox Injection
Moderate to Severe Glabellar Lines
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines.
- Trial name
- NCT06583486
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 488 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Muscle Spasticity, Cerebrovascular Accident
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.
- Trial name
- NCT00234546
- Testing
- Botulinum toxin type A
- Where
- 5 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 162 people
- Sponsor
- Ipsen
Masseter Muscle Prominence
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a…
- Trial name
- MMP Japan 080 (NCT06137287)
- Testing
- BOTOX
- Where
- 18 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Lower Limb Spasticity
RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke
The objective of this study is to demonstrate the effect of intramuscular BoNT-A injections in relieving pain, in a broad population of patients who suffer pain as the primary problem associated with spasticity.
- Trial name
- RELIEF (NCT02020980)
- Testing
- Botulinum toxin type A
- Where
- 28 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Ipsen
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by…
- Trial name
- IC/BPS POC (NCT05141006)
- Testing
- BOTOX
- Where
- 43 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- AbbVie
Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
- Trial name
- NCT03786770
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Revance Therapeutics, Inc.
Torticollis (Spasmodic)
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).
- Trial name
- NCT02706795
- Testing
- DaxibotulinumtoxinA
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Revance Therapeutics, Inc.
Hemifacial Spasm
Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm
To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.
- Trial name
- NCT00276315
- Testing
- Botulinum toxin type A
- Where
- 4 sites in China
- Volunteers
- 332 people
- Sponsor
- Ipsen
Chronic Migraine
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
A study, multi-center, randomized, double-blind, placebo parallel-controlled method, will be carried out to evaluate the safety and efficacy of Botulinum Toxin Type A for injection (HengLi®) for prophylactic treatment with…
- Trial name
- NCT02291380
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 288 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Glabellar Lines
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05496335
- Testing
- AGN-151586, BOTOX
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- AbbVie
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Platysma Prominence
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.
- Trial name
- NCT04994535
- Testing
- OnabotulinumtoxinA
- Where
- 34 sites in United States, Belgium and 3 more
- Volunteers
- 426 people
- Sponsor
- AbbVie
Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury
Dysport® Adult Lower Limb Spasticity Follow-on Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01251367
- Testing
- Botulinum toxin type A
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 352 people
- Sponsor
- Ipsen
Post-Operative Atrial Fibrillation
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of…
- Trial name
- NCT03779841
- Testing
- AGN-151607
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 323 people
- Sponsor
- AbbVie
Overactive Bladder
A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)
This is a multicenter, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of Botulinus Toxin Type A for Injection (HengLi®) in patients with overactive bladder (OAB) .
- Trial name
- NCT02786407
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 216 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Cervical Dystonia
Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of two doses of daxibotulinumtoxinA (DAXI) for injection (high-dose; low-dose in adult subjects with isolated (primary) cervical dystonia…
- Trial name
- ASPEN-1 (NCT03608397)
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 75 sites in United States, Austria and 7 more
- Volunteers
- 301 people
- Sponsor
- Revance Therapeutics, Inc.
Plantar Fasciitis
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
- Trial name
- NCT02973269
- Testing
- daxibotulinumtoxin type A
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Hyperfunctional facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05013424
- Testing
- Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Allergan